Last reviewed · How we verify
NCT03868865
Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy
NA trial testing Integrative mind-body-medicine group program in Breast Cancer in 57 participants. Completed in 7 April 2015.
7 April 2015
Quick facts
| Lead sponsor | Universität Duisburg-Essen |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 57 |
| Start date | 7 August 2012 |
| Primary completion | 7 April 2015 |
| Estimated completion | 7 April 2015 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Integrative mind-body-medicine group program
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Chemotherapy — all drugs for Chemotherapy →
- Mind-Body-Medicine — all drugs for Mind-Body-Medicine →
- Acupuncture — all drugs for Acupuncture →
Sponsor
Universität Duisburg-Essen — full company profile →
Who can join
18 and older, female only, with Breast Cancer or Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study was to evaluate a new integrative day-care clinic concept for breast cancer patients receiving chemotherapy. This is an explorative pilot study. Therefore, all outcomes are analyzed exploratively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03868865
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Universität Duisburg-Essen trials
Trials by the same sponsor.
- NCT07273045 — A Comprehensive, Multinational GIST Registry · not yet recruiting
- NCT07255313 — Strengthening Health Literacy in Healthcare Workers Through Mind Body Medicine and Nutrition · NA · recruiting
- NCT05645588 — Pranayama for Posttraumatic Stress Disorder · NA · withdrawn
- NCT06666296 — Sustainable Eating for a Healthy Tomorrow - Effectiveness of Digital Nutrition Workshops to Implement the Planetary Heal · NA · completed
- NCT06204458 — Mild Water-filtered Infrared-A Whole-body Hyperthermia in Patients With Post-COVID Syndrome (HyPoCo) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03868865 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universität Duisburg-Essen
- Last refreshed: 11 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03868865.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing